QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models
暂无分享,去创建一个
Manish Gupta | Shepard Smithline | Craig J. Thalhauser | Yougan Cheng | Jyotsna Pagidala | Marko Miladinov | Heather E. Vezina | Tarek A. Leil | Brian J. Schmidt | H. Vezina | Yougan Cheng | T. Leil | M. Miladinov | B. Schmidt | Manish Gupta | S. Smithline | Jyotsna Pagidala
[1] S. Visser,et al. Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.
[2] M. J. Moné,et al. Modeling and Simulation Tools: From Systems Biology to Systems Medicine. , 2016, Methods in molecular biology.
[3] Ravi Iyengar,et al. Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .
[4] Henning Schmidt,et al. Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[5] J. Lucas,et al. A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate , 2014, The AAPS Journal.
[6] Neil Benson,et al. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.
[7] Willy Bauwens,et al. Optimising the convergence of a Sobol’ sensitivity analysis for an environmental model: application of an appropriate estimate for the square of the expectation value and the total variance , 2012 .
[8] L. Weiner,et al. Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs , 2015, Journal of clinical pharmacology.
[9] Ronan M. T. Fleming,et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.
[10] S. Sadekar,et al. Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection , 2015, The AAPS Journal.
[11] Stephan Schmidt,et al. Coping with time scales in disease systems analysis: application to bone remodeling , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[12] Francesco Pozzi,et al. Exponential smoothing weighted correlations , 2012 .
[13] Jerzy W. Jaromczyk,et al. Using HPC for teaching and learning bioinformatics software: Benefits and challenges , 2013, BMC Bioinformatics.
[14] H. Vezina,et al. Nonclinical Pharmacology and Mechanistic Modeling of Antibody–Drug Conjugates in Support of Human Clinical Trials , 2016 .
[15] B. Agoram,et al. Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models , 2014, CPT: pharmacometrics & systems pharmacology.
[16] S. Marshall,et al. Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.
[17] Stephen C. Ekker,et al. Mojo Hand, a TALEN design tool for genome editing applications , 2013, BMC Bioinformatics.
[18] E. Diamandis,et al. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.
[19] David J. Klinke,et al. Integrating Epidemiological Data into a Mechanistic Model of Type 2 Diabetes: Validating the Prevalence of Virtual Patients , 2008, Annals of Biomedical Engineering.
[20] M. Birtwistle,et al. A General Network Pharmacodynamic Model–Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway , 2014, CPT: pharmacometrics & systems pharmacology.
[21] K Gadkar,et al. A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.
[22] I. Pastan,et al. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. , 2012, Cancer research.
[23] John D. Davis,et al. A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations , 2014, CPT: pharmacometrics & systems pharmacology.
[24] Albert Wang,et al. Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..
[25] Paul Polakis,et al. Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.
[26] Aman P. Singh,et al. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1) , 2016, The AAPS Journal.
[27] Gabriel Helmlinger,et al. A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design , 2015, PloS one.
[28] Intawat Nookaew,et al. The RAVEN Toolbox and Its Use for Generating a Genome-scale Metabolic Model for Penicillium chrysogenum , 2013, PLoS Comput. Biol..
[29] P Vicini,et al. A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1—Theoretical Model , 2014, CPT: pharmacometrics & systems pharmacology.
[30] Hans Othmer,et al. A Model for Direction Sensing in Dictyostelium discoideum: Ras Activity and Symmetry Breaking Driven by a Gβγ-Mediated, Gα2-Ric8 -- Dependent Signal Transduction Network , 2015, PLoS Comput. Biol..
[31] Christina Peters,et al. Antibody–drug conjugates as novel anti-cancer chemotherapeutics , 2015, Bioscience reports.
[32] MN Trame,et al. Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.
[33] F Mentré,et al. Best Practices in Population Modeling Should Always Be Evolving , 2013, CPT: pharmacometrics & systems pharmacology.
[34] P. Lyster,et al. NIH Support for the Emergence of Quantitative and Systems Pharmacology , 2013, CPT: pharmacometrics & systems pharmacology.
[35] D. Lauffenburger,et al. Receptors: Models for Binding, Trafficking, and Signaling , 1993 .
[36] T. R. Johnson,et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin , 2016, The AAPS Journal.
[37] A. Saltelli,et al. Making best use of model evaluations to compute sensitivity indices , 2002 .
[38] Richard J. Allen,et al. Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models , 2015 .
[39] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[40] David Schrama,et al. Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.
[41] Dhaval K. Shah,et al. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[42] MC Peterson,et al. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.
[43] CM Friedrich,et al. A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.
[44] Christopher R. Myers,et al. Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..
[45] Fergal P. Casey,et al. Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis , 2013, BMC Bioinformatics.
[46] K. Gadkar,et al. Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates , 2014, Pharmaceutical Research.
[47] Jason A. Papin,et al. Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.
[48] DA Lauffenburger,et al. GPS for QSP: A Summary of the ACoP6 Symposium on Quantitative Systems Pharmacology and a Stage for Near‐Term Efforts in the Field , 2016, CPT: pharmacometrics & systems pharmacology.
[49] E. Somersalo,et al. The Metabolism of Neurons and Astrocytes Through Mathematical Models , 2012, Annals of Biomedical Engineering.
[50] M. Jamei,et al. Evaluating the efficiency of payload delivery by ADCs using a minimal PBPK model , 2015 .
[51] Saltelli Andrea,et al. Global Sensitivity Analysis: The Primer , 2008 .
[52] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[53] Greg M Thurber,et al. A mechanistic compartmental model for total antibody uptake in tumors. , 2012, Journal of theoretical biology.
[54] Byungkook Lee,et al. Modeling Recombinant Immunotoxin Efficacies in Solid Tumors , 2008, Annals of Biomedical Engineering.
[55] Robert J. Neely,et al. An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. , 2015, Bioanalysis.
[56] R. Iyengar,et al. Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.
[57] A. Scott,et al. Antibody–Drug Conjugates for Cancer Therapy , 2016, Biomedicines.
[58] Tarek A. Leil,et al. Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..
[59] Laurent Ducry,et al. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.
[60] A. Tolcher,et al. A phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] B J Schmidt,et al. Systems Biology for Simulating Patient Physiology During the Postgenomic Era of Medicine , 2014, CPT: pharmacometrics & systems pharmacology.
[62] Joshua A. Lerman,et al. COBRApy: COnstraints-Based Reconstruction and Analysis for Python , 2013, BMC Systems Biology.
[63] K. Gadkar,et al. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics , 2016, The AAPS Journal.
[64] M. Mavrovouniotis,et al. Simplification of Mathematical Models of Chemical Reaction Systems. , 1998, Chemical reviews.